首页> 外文期刊>Experimental and clinical transplantation >Is It Justified to Use Liver Grafts From Living Donors for Retransplant? A Single-Center Experience
【24h】

Is It Justified to Use Liver Grafts From Living Donors for Retransplant? A Single-Center Experience

机译:是否有理由使用肝脏移植从活捐赠者进行重新制定者?单中心体验

获取原文
           

摘要

Objectives: Liver retransplant is considered the only hope for patients with irreversible graft failure after primary transplant. In most Western centers, retrans?-plant is done mainly from deceased donors; so far, only few published studies have reported on outcomes of liver retransplant with living donors. In this study, our aim was to analyze the outcomes of living-donor liver retransplant. Materials and Methods: Patients who underwent liver retransplant between February 2011 and February 2019 were included in the study. Preoperative, operative, and postoperative data were analyzed. Results from 2 patient groups were compared: liver retransplant with living donors and liver retransplant with deceased donors. Results: Thirty-two patients underwent liver retrans?-plant (21 adult and 11 pediatric patients). The most common indications for liver retransplant were hepatic artery thrombosis (28.5%) and primary graft nonfunction (23.8%) in adults and hepatic artery thrombosis (45.5%) and chronic rejection (36.4%) in pediatric patients. Seventeen retransplant patients (53.1%) required early retransplant (within 1 mo), mainly due to hepatic artery thrombosis (52.9%) and primary graft nonfunction (35.3%). Late retransplant was mainly due to chronic rejection (40%) and recurrence of primary disease (26.7%). Seventeen patients (53.1%) underwent living-donor retransplant, and 5 donors underwent robotic right hepatectomy. Graft and patient survival rates at 1, 3, and 5 years were 81.3% for living-donor and 51.4% for deceased-donor liver retransplant recipients ( P = .08). On multivariate analyses, we observed significant differences between both groups in pretransplant Model for End-Stage Liver Disease and Pediatric End-Stage Liver Disease scores ( P = .05), preoperative international normalized ratio ( P = .012), and cold ischemia time ( P = .046). Conclusions: The use of living donors for liver retransplant, despite its technical demand, was shown to be a safe and feasible option, especially when there is scarcity of deceased donors.
机译:目的:肝重载植物被认为是初次移植后不可逆移植物失败的患者的唯一希望。在大多数西方中心,批发? - 普班主要来自死者捐赠者;到目前为止,只有很少的公布研究报告了肝脏重新纳入生活捐赠者的结果。在这项研究中,我们的目的是分析患有患者肝脏重传的结果。材料与方法:在2011年2月和2019年2月之间接受肝重传的患者纳入该研究。分析了术前,手术和术后数据。比较了2个患者群的结果:肝脏重新筛选活性捐赠者和肝脏重新筛选死者的供体。结果:32例患者接受了肝脏旋转? - 植物(21例成人和11名儿科患者)。肝重载剂的最常见适应症是肝动脉血栓形成(28.5%)和初级接枝非功能(23.8%)在成人和肝动脉血栓形成(45.5%)和儿科患者的慢性排斥(36.4%)。 17名重新分析患者(53.1%)需要早期重称(在1月内),主要是由于肝动脉血栓形成(52.9%)和初级接枝非功能(35.3%)。晚期重新分析主要是由于慢性排斥反应(40%)和原发性疾病的复发(26.7%)。 17名患者(53.1%)接受了营养助剂重新分析,5名捐赠者接受了机器人右肝切除术。嫁接和患者存活率为1,3和5岁为81.3%的饲料供体为81.3%,51.4%用于死亡供体肝重载受者(P = .08)。在多变量分析中,我们观察到前阶段肝病和儿科终末期肝病分数的预先体验模型中的两个群体之间的显着差异(p = .05),术前国际归一化比(P = .012)和冷缺血时间(p = .046)。结论:尽管有技术需求,但肝脏重新筛选的生活捐赠者的使用被证明是一种安全可行的选择,特别是当死者捐赠者稀缺时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号